Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3BCHECHRM1CHRM2CHRM3CHRM4CHRNA3CHRNA4CHRNB2CHRNB4ESR1ESR2GABRA1GABRB1GABRG2GBA1GHSRHRH1HTR1DHTR2AMAOBOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8UGCGrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Triaziquone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 2/20 | 0.31 |
| ▸ | TDP2 | O95551 | 2/20 | 0.31 |
| ▸ | NSD2 | O96028 | 2/20 | 0.31 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | GALK1 | P51570 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triaziquone SCHEMBL4334317 | 0.86 | DNMT1 (0.40) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL6535620 | 0.82 | DNMT1 (0.40) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL10583104 | 0.81 | DNMT1 (0.47) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL4608905 | 0.81 | DNMT1 (0.43) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL8926769 | 0.80 | DNMT1 (0.42) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL112498 | 0.78 | DNMT1 (0.39) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL14862047 | 0.76 | DNMT1 (0.44) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL11545270 | 0.75 | DNMT1 (0.42) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL322828 | 0.75 | DNMT1 (0.42) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL9678206 | 0.75 | DNMT1 (0.39) | DNMT1TP53MAPTSTAT3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6573237-B2 | Soluble formulation comprising nicotinamide, hydrophobic preservative, and medically useful peptide or protein selected from follicle stimulating hormone and its variants | ELI LILLY AND COMPANY | 2003-06-03 | — | — | US | disclosed |